Bryan Johnson, the 47-year-old IT entrepreneur and anti-ageing advocate, has stopped his five-year regimen of taking an age-reversing drug (immunosuppressant rapamycin). Although he had been using the drug in hopes of extending his life and reversing his biological age, Johnson concluded that the medication’s negligible benefits were not worth the negative side effects.

Rapamycin is a drug often given to transplant patients to help prevent organ rejection. Bryan Johnson, who used a very strong version of the drug to try to reverse his age, now believes it may have done more harm than good.

Bryan announced, "On September 28, I decided to stop rapamycin, ending nearly five years of experimenting with this drug for its potential to increase longevity." Johnson, who is featured in the new Netflix documentary Don’t Die: The Man Who Wants to Live Forever shared this decision after careful consideration.

He said, "Even though early trials showed great potential, my team and I decided the side effects of long-term rapamycin use aren't worth the benefits." He explained that studies revealed rapamycin could cause issues like insulin resistance, and glucose intolerance, and affect lipid metabolism. Johnson admitted to stopping the drug after filming his Netflix documentary Don’t Die: The Man Who Wants to Live Forever, acknowledging that it may have had the opposite effect on his health.

In his efforts to slow down or even reverse the ageing process, Bryan Johnson spends $2 million a year on medical tests and treatments. He also follows a strict diet, sleep schedule, and exercise routine to support his goal.

Bryan Johnson, known for founding Braintree (which was acquired by PayPal), has been dedicated to anti-ageing efforts since selling his company. He reportedly underwent a complete plasma exchange, where pure albumin replaced the fluid in his body. This was different from his controversial 2023 procedure, where he exchanged blood with his son, referred to as his "blood boy." Johnson is also the founder of Kernel, a neurotechnology firm that develops helmets to measure brain activity.